These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 2893864)

  • 1. Randomised trial of alternative formulations of oral poliovaccine in Brazil.
    Patriarca PA; Laender F; Palmeira G; Oliveira MJ; Lima Filho J; Dantes MC; Cordeiro MT; Risi JB; Orenstein WA
    Lancet; 1988 Feb; 1(8583):429-33. PubMed ID: 2893864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of bivalent types 1 and 3 oral poliovirus vaccine: a randomised, double-blind, controlled trial.
    Sutter RW; John TJ; Jain H; Agarkhedkar S; Ramanan PV; Verma H; Deshpande J; Singh AP; Sreevatsava M; Malankar P; Burton A; Chatterjee A; Jafari H; Aylward RB
    Lancet; 2010 Nov; 376(9753):1682-8. PubMed ID: 20980048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial.
    Qiu J; Yang Y; Huang L; Wang L; Jiang Z; Gong J; Wang W; Wang H; Guo S; Li C; Wei S; Mo Z; Xia J
    Hum Vaccin Immunother; 2017 Jun; 13(6):1-10. PubMed ID: 28362135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial.
    Estívariz CF; Anand A; Gary HE; Rahman M; Islam J; Bari TI; Wassilak SG; Chu SY; Weldon WC; Pallansch MA; Heffelfinger JD; Luby SP; Zaman K
    Lancet Infect Dis; 2015 Aug; 15(8):898-904. PubMed ID: 26093980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from Cuba: mass campaign administration of trivalent oral poliovirus vaccine and seroprevalence of poliovirus neutralizing antibodies.
    Mas Lago P; Ramon Bravo J; Andrus JK; Comellas MM; Galindo MA; de Quadros CA; Bell E
    Bull World Health Organ; 1994; 72(2):221-5. PubMed ID: 8205641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial.
    Asturias EJ; Bandyopadhyay AS; Self S; Rivera L; Saez-Llorens X; Lopez E; Melgar M; Gaensbauer JT; Weldon WC; Oberste MS; Borate BR; Gast C; Clemens R; Orenstein W; O'Ryan G M; Jimeno J; Clemens SA; Ward J; Rüttimann R;
    Lancet; 2016 Jul; 388(10040):158-69. PubMed ID: 27212429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study.
    Taniuchi M; Famulare M; Zaman K; Uddin MJ; Upfill-Brown AM; Ahmed T; Saha P; Haque R; Bandyopadhyay AS; Modlin JF; Platts-Mills JA; Houpt ER; Yunus M; Petri WA
    Lancet Infect Dis; 2017 Oct; 17(10):1069-1079. PubMed ID: 28693854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Thermostability and immunogenicity of trivalent oral poliovirus vaccine produced by different countries].
    Kong J
    Zhonghua Liu Xing Bing Xue Za Zhi; 1993 Jun; 14(3):151-4. PubMed ID: 8221837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
    Duintjer Tebbens RJ; Hampton LM; Thompson KM
    BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study.
    O'Ryan M; Bandyopadhyay AS; Villena R; Espinoza M; Novoa J; Weldon WC; Oberste MS; Self S; Borate BR; Asturias EJ; Clemens R; Orenstein W; Jimeno J; Rüttimann R; Costa Clemens SA;
    Lancet Infect Dis; 2015 Nov; 15(11):1273-82. PubMed ID: 26318714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials.
    John TJ; Jain H; Ravishankar K; Amaresh A; Verma H; Deshpande J; Pallansch MA; Singh AP; Sreevatsava M; Burton A; Malankar P; Chatterjee A; Sutter RW
    Vaccine; 2011 Aug; 29(34):5793-801. PubMed ID: 21641951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of type 1 and type 3 oral monovalent poliovirus vaccines in newborns in Africa.
    Waggie Z; Geldenhuys H; Sutter RW; Jacks M; Mulenga H; Mahomed H; De Kock M; Hanekom W; Pallansch MA; Kahn AL; Burton AH; Sreevatsava M; Hussey G
    J Infect Dis; 2012 Jan; 205(2):228-36. PubMed ID: 22158680
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early immunization of neonates with trivalent oral poliovirus vaccine.
    Weckx LY; Schmidt BJ; Herrmann AA; Miyasaki CH; Novo NF
    Bull World Health Organ; 1992; 70(1):85-91. PubMed ID: 1314711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decision analysis in planning for a polio outbreak in the United States.
    Jenkins PC; Modlin JF
    Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A comparison of the effectiveness of mass immunization campaign of trivalent oral poliovirus vaccine (TOPV) by epidemiological serosurvey. Shandong Collaborating Group for Poliomyelitis Control and Surveillance, Jinan, Shandong].
    Xu A
    Zhonghua Liu Xing Bing Xue Za Zhi; 1992 Oct; 13(5):261-4. PubMed ID: 1338626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review.
    Patriarca PA; Wright PF; John TJ
    Rev Infect Dis; 1991; 13(5):926-39. PubMed ID: 1660184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early priming with inactivated poliovirus vaccine (IPV) and intradermal fractional dose IPV administered by a microneedle device: A randomized controlled trial.
    Anand A; Zaman K; Estívariz CF; Yunus M; Gary HE; Weldon WC; Bari TI; Steven Oberste M; Wassilak SG; Luby SP; Heffelfinger JD; Pallansch MA
    Vaccine; 2015 Nov; 33(48):6816-22. PubMed ID: 26476367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants.
    Wright PF; Connor RI; Wieland-Alter WF; Hoen AG; Boesch AW; Ackerman ME; Oberste MS; Gast C; Brickley EB; Asturias EJ; Rüttimann R; Bandyopadhyay AS
    Lancet Infect Dis; 2016 Dec; 16(12):1377-1384. PubMed ID: 27638357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immune interference of enteroviruses to immune response of TOPV in subtroptical areas].
    Wu CM; Zheng HY; Ren YL
    Zhonghua Liu Xing Bing Xue Za Zhi; 1996 Aug; 17(4):233-5. PubMed ID: 9387590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monovalent type 1 oral poliovirus vaccine in newborns.
    el-Sayed N; el-Gamal Y; Abbassy AA; Seoud I; Salama M; Kandeel A; Hossny E; Shawky A; Hussein HA; Pallansch MA; van der Avoort HG; Burton AH; Sreevatsava M; Malankar P; Wahdan MH; Sutter RW
    N Engl J Med; 2008 Oct; 359(16):1655-65. PubMed ID: 18923170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.